|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Considerations for Managing Patients as They Progress to Castration-Resistant Prostate Cancer
|
Tian Zhang, MD, MHS
Tian Zhang outlines management strategies for patients progressing from metastatic hormone-sensitive to castration-resistant prostate cancer with upfront expectation-setting discussions.
|
|
|
|
|
|
|
|
|
|
|
|
Selecting Patients for Triplet Therapy in Metastatic Prostate Cancer
|
|
A. Oliver Sartor, MD
|
| Zachary Klaassen speaks with Oliver Sartor about treatment intensification in metastatic hormone-sensitive prostate cancer, focusing on triplet therapy selection.
|
|
|
|
|
|
|
|
|
|
|
|
|
How Patient Function and Independence Are Changing Advanced Prostate Cancer Care
|
Kristine Peregrino Lacuna, MD
In this conversation, Kristine Lacuna highlights the importance of balancing disease control with quality of life, noting that treatment decisions should preserve patient function, independence, and daily living, not just improve survival outcomes.
|
|
|
|
|
|
|
|
|
|
|
| Treatment Intensification in the mCSPC Landscape: Real-World Evidence from 4,559 Patients in the CAPRI-3 Registry
|
| Kim J. Van der Velden, BSc
|
| A real-world CAPRI-3 registry analysis of 4,559 men with mCSPC found that ADT alone was still the most common treatment, and treatment intensification was used much more often in high-volume than low-volume disease. Intensification did not improve overall survival in the full cohort, but it was associated with a clear survival benefit in high-volume patients, supporting treatment decisions based on disease burden and patient fitness.
|
|
|
|
|
|
| Potential for Drug-Drug Interactions with Novel ARTAs and Concomitant Medications: Analysis Based on the mHSPC Patients in the Real-World Evidence RECOMMEND Study
|
| Amit Bahl, MBBS, FRCR
|
| The RECOMMEND real-world cohort suggests variability in potential drug–drug interactions across ARPIs, with darolutamide showing a lower proportion of potential interactions in this analysis. These findings may be relevant when treating patients with significant comorbidities or polypharmacy, though interpretation should be considered in the context of study design.
|
|
|
|
|
|
|
|
|
|
|
| Quality of Life, Adherence, and Adverse Events Among Patients with Advanced Prostate Cancer Treated with Relugolix: 6-Month Results of the OPTYX Multicenter Registry
|
| Rana McKay, MD
|
| In the 6-month OPTYX registry analysis, real-world relugolix use was associated with stable quality of life, high adherence, and low rates of reported adverse events. Among 999 patients, the majority reported consistent treatment adherence, with relatively few discontinuations due to toxicity, supporting its tolerability in routine clinical practice.
|
|
|
|
|
|
| Harnessing Caregiver Support to Improve Shared Decision-Making in Metastatic Prostate Cancer Treatment: A US-Based Quantitative Survey
|
| Daniel George, MD
|
| Daniel George presents the ASCO GU 2026 caregiver survey which found that caregivers are deeply involved in metastatic prostate cancer care, with most attending visits, helping manage medications, and participating in treatment decisions. Despite this, many felt under-supported, and women tended to take on more emotional and symptom-monitoring tasks, highlighting a need for better caregiver-focused resources and decision-support tools.
|
|
|
|
|
|
Real-World Burden and Management of Late Genitourinary Toxicity after Prostate Radiotherapy: Insights from IRRADIaTE, the Italian Registry of Radiotherapy-Associated Disorders and Urological Treatment & Evaluation - Beyond the Abstract
|
| Riccardo Bertolo, MD, PhD and Alessandro Antonelli, MD
|
| IRRADIaTE was a prospective Italian registry of 321 men who developed severe late genitourinary toxicity after prostate radiotherapy, showing that these complications are often delayed, progressive, and resource-intensive, with many patients requiring repeated procedures or hospitalization. The study was not designed to estimate overall incidence or prove causation, but it highlights the need for long-term survivorship follow-up and better coordination between radiation oncology and urology.
|
|
|
|
|
|
|
|
|
|
|
